常染色体显性多囊肾病的药物重定位
本文综述常染色体显性多囊肾病的药物重定位策略。托伐普坦是目前唯一获批用于快速进展患者的药物,但受耐受性和肝毒性限制。文章聚焦通过疾病发病机制和信号通路识别候选药物,以及高成功概率候选药物的优先级排序与实施。
要点
- 托伐普坦是唯一获批治疗快速进展的常染色体显性多囊肾病患者的药物。
- 托伐普坦因水排泄效应导致的耐受性下降和潜在肝毒性而使用受限。
- 药物重定位因成本和时间效率及已知药代动力学与安全性特征而日益受青睐。
核心结论
- 寻找更有效药物以延缓常染色体显性多囊肾病进展紧迫且具有挑战性,药物重定位是识别已获批或研究中药物的新临床适应证的策略。
研究设计与样本
- 本文为综述,聚焦识别治疗常染色体显性多囊肾病合适候选药物的重定位方法,以及高成功概率候选药物的优先级排序与实施。
主要发现
- 通过理解疾病发病机制和信号通路来识别候选药物是本文强调的重点。
- 药物重定位因成本效率和时间效率以及已知的药代动力学和安全性特征而日益成为有吸引力的选择。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Autosomal dominant polycystic kidney disease is characterized by progressive kidney cyst formation that leads to kidney failure. Tolvaptan, a vasopressin 2 receptor antagonist, is the only drug approved to treat patients with autosomal dominant polycystic kidney disease who have rapid disease progression. The use of tolvaptan is limited by reduced tolerability from aquaretic effects and potential hepatotoxicity. Thus, the search for more effective drugs to slow down the progression of autosomal dominant polycystic kidney disease is urgent and challenging. Drug repurposing is a strategy for identifying new clinical indications for approved or investigational medications. Drug repurposing is increasingly becoming an attractive proposition because of its cost-efficiency and time-efficiency and known pharmacokinetic and safety profiles. In this review, we focus on the repurposing approaches to identify suitable drug candidates to treat autosomal dominant polycystic kidney disease and prioritization and implementation of candidates with high probability of success. Identification of drug candidates through understanding of disease pathogenesis and signaling pathways is highlighted.
引用
- Zhou JX, Torres VE. Drug repurposing in autosomal dominant polycystic kidney disease. Kidney Int. 2023. PMID: 36870435. doi:10.1016/j.kint.2023.02.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。